Breakthrough technologies to treat complex neurological conditions

Our Technologies

Alcyone Lifesciences Enters into a Feasibility Study Agreement with Pfizer to Evaluate Alcyone's proprietary Pulsar™ Advanced Intrathecal Precision Delivery Platform Technology for use in Gene Therapy Targeting Central Nervous System Disorders

Mission

At Alcyone, we are committed to developing biologically inspired and clinically relevant solutions to significantly enhance current treatment modes for patients suffering from chronic neuropathological conditions.

About Alcyone

Our Technologies

Alcyone MEMS Cannula (AMC™)*

Pulsar CSF Dynamic Intrathecal System**

ReFlow™ Ventricular System for Hydrocephalus***

All Technologies

Upcoming Conferences & Events

September 23, 2017 - September 25, 2017
Kobe, Japan

Alcyone's Andrew East will be speaking regarding the ReFlow™ Ventricular System
September 23, 2017, 5:10pm, Hall 1
October 25, 2017 - October 28, 2017
Orlando, FL
November 15, 2017 - November 19, 2017
San Francisco, CA

*Alcyone will be sponsoring the SCI-DOT/SNO Joint Conference, occuring from November 15-16.
January 8, 2018 - January 11, 2018
San Francisco, CA
March 2018
TBD

*Alcyone previously sponsored the 2017 ICCS/SRHSB Joint Conference
May 16, 2018 - May 19, 2018
Boston, MA

*The Alcyone MEMS Cannula (AMC™) System, a neuro-ventricular cannula, has US Food and Drug Administration (FDA) 510(k) clearance, Health Canada Licensing, and CE Marking. It is indicated for use in the U.S. and Canada for the injection of Cytarabine or the removal of cerebrospinal fluid from the ventricles of the brain during an intracranial procedure, and approved in Europe for injection or removal of substances from the brain and/or ventricles of the brain during intracranial procedures. The AMC is a dual-lumen, MR-compatible injection and aspiration cannula and can be used with existing commercial imaging and stereotactic systems. The AMC is not intended for implant, and it is intended for single patient use only.

** The Pulsar System is not yet available for commercial use and has not yet been cleared by the FDA.

*** The ReFlow™ Ventricular System is not available for commercial use. The ReFlow™ Ventricular System is pending 510(k) clearance from the U.S. Food and Drug Administration, and CE Marking.